COVID Alert updated to help evaluate its effectiveness in reducing the spread of COVID-19 Font : A-A+ OTTAWA, ON, Feb. 9, 2021 /CNW/ - As we continue to deal with the health and economic impacts of the pandemic, we need to work together to contain the virus. Millions of Canadians are downloading and using the free COVID Alert app in an effort to help prevent the spread of COVID-19. Today, the Minister of Health, the Honourable Patty Hajdu, and the Minister of Digital Government, the Honourable Joyce Murray, announced that the COVID Alert app will be updated to help measure its uptake, performance and effectiveness in limiting the spread of COVID-19. This will be done through the collection of certain metrics, while maintaining strong privacy measures to protect confidentiality.
Medical Tablet integrates with Philips advanced IntelliVue XDS software to enable remote access of patient monitoring information, allowing clinicians to care for patients outside of the hospital setting
Independent Tests Show Senturion+ Viruend Adsorptive Filtration Material Eliminates 98.8% of SARS-CoV-2 Virus Font : A-A+
Advanced, nature-based material catches and kills at least 25% more SARS-CoV-2 and other viruses than standard N95 masks HONOLULU, Jan. 21, 2021 /PRNewswire-PRWeb/ Senturion+ announced that its patented Viruend filtration material has been proven to block and inactivate the SARS-CoV-2 virus with a 98.8% removal efficacy rate. Scientists from the Battelle Memorial Institute, a private nonprofit applied science and technology laboratory, tested Viruend in a composited paper media against live SARS-CoV-2 and determined that it significantly exceeds the filtration capabilities of standard N95 masks. Battelle evaluated the filtration efficacy of Senturion+ Viruend and reported it achieved 98.8% removal of infectious SARS-CoV-2 as compared to 65.4% removal in a concurrent [Viruend] control filter. The report further stated: [Results] may indicate that t
Myriad Genetics Receives Reimbursement for BRACAnalysis® Diagnostic System in Japan Font : A-A+
from Treatment with Lynparza
More Than 20,000 Patients in Japan Now Qualify for Genetic Testing
SALT LAKE CITY, Jan. 19, 2021 (GLOBE NEWSWIRE) In an announcement that will help more people with advanced prostate and pancreatic cancers in Japan, Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will receive reimbursement for its BRACAnalysis
® Diagnostic System, which helps physicians determine whether certain patients will qualify and potentially benefit from treatment with the PARP inhibitor, Lynparza (olaparib). BRACAnalysis was approved by Japans Ministry of Health, Labour and Welfare (MHLW) in October 2020 as a companion diagnostic for these indications and the reimbursement decision is now in effect.